a combination chemotherapy program using methotrexate , bleomycin , doxorubicin , cyclophosphamide , vincristine , and dexamethasone ( m-bacod ) , which resulted in a high complete response rate and prolonged disease-free survival in lymphomas of the unfavorable diffuse histiocytic and diffuse undifferentiated histopathologic subgroups , was administered to 44 patients with advanced favorable and intermediate-prognosis non-hodgkin 's lymphomas , including nodular lymphoma of the poorly differentiated lymphocytic , mixed , and histiocytic subtypes , and diffuse lymphoma of the poorly differentiated lymphocytic or mixed histologic subtypes .
C0013089
doxorubicin
C0083304
m-bacod